Blomage has acquired Vivacy. Blomage was advised by Dyens & Co.

vivacy-logo.png
bloomage-logo.png

Bloomage Biotechnology (Beijing, China), a Hong Kong Stock Exchange-listed biotechnology company specialized in the hyaluronic acid (HA) industry,  purchased a 33.4% stake in Laboratoires Vivacy SAS for 10.8x sales and a cash consideration of €177m for 100% of the shares. It paves the way for the transformation of Bloomage into a high-end, integrated global Medical Aesthetics player and is consistent with their strategy of premiumization by adding dermal filler Stylage® to complement their brand BioHyalux®.

Dyens & Co. was the sole advisor to Bloomage Biotechnology (Beijing, China), a Hong Kong Stock Exchange-listed biotechnology company specialized in the hyaluronic acid (HA) industry.

 

 

 
healthcareMichel Dyens